

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA - Dacomitinib for untreated EGFR-positive non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During consultation, a stakeholder highlighted that in the pivotal clinical trial, effectiveness of the technology differed between ethnic groups.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The Committee need to consider the generalisability of the evidence to all ethnic groups and provide a clear clinical rationale for their conclusion. If appropriate, the committee should consider whether the expected marketing authorisation limits the indication according to ethnic group, and discuss with clinical experts.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No changes required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No changes required.

Approved by Associate Director (name): Jasdeep Hayre

Date: 09/10/2018